• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新辅助放化疗后手术治疗食管癌的长期疗效:一项针对102例患者的单机构回顾性研究

[Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients].

作者信息

Ruffier-Loubière A, Janoray G, Chapet S, de Calan L, Dumont P, Dorval É, Orain I, Calais G

机构信息

Clinique d'oncologie-radiothérapie, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France.

Clinique d'oncologie-radiothérapie, hôpital Bretonneau, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex 9, France.

出版信息

Cancer Radiother. 2015 Aug;19(5):322-30. doi: 10.1016/j.canrad.2015.04.004. Epub 2015 Jul 26.

DOI:10.1016/j.canrad.2015.04.004
PMID:26215366
Abstract

PURPOSE AND OBJECTIVES

To report survival and morbidity of a large homogeneous cohort of patients with a locally advanced esophageal or cardia carcinoma and put in evidence predictive factors of locoregional control and survival.

PATIENTS AND METHODS

Hundred and two patients were treated at the university hospital of Tours between 1990 and 2010 and received neo-adjuvant chemoradiation therapy with external irradiation (40Gy-44Gy) and two courses of chemotherapy (5-fluoro-uracile and cisplatine). Esophagectomy associated with lymph node dissection was performed about ten weeks after the end of chemoradiation therapy.

RESULTS

The median follow-up was 22.4 months [6-185 months]. The overall survival rates at 2 and 5years were 53% and 27%, respectively. The median overall survival was estimated at 27months. The overall 2-year survival between patients "responders" and patients "non-responders" was 67% vs 26%, respectively (P<0.0001). In case of histological response, there was a benefit in terms of overall survival (P<0.0001), locoregional control (P<0.0036) and disease-free survival (P<0.001). Overall survival at 2years was 64% for ypN0 group vs 32% for ypN1 group (P<0.0001). The median survival was estimated at 37months against 15months in the absence of lymph node involvement (P<0.0001).

CONCLUSION

Our results in terms of survival, tolerance and morbidity and mortality were comparable to those in the literature. Complete histological response of lymph node was associated with an improvement of local control, disease-free survival and overall survival.

摘要

目的和目标

报告一大组局部晚期食管癌或贲门癌患者的生存率和发病率,并找出局部区域控制和生存的预测因素。

患者和方法

1990年至2010年期间,图尔大学医院对102例患者进行了治疗,这些患者接受了新辅助放化疗,包括外照射(40Gy - 44Gy)和两个疗程的化疗(5-氟尿嘧啶和顺铂)。放化疗结束约十周后进行了食管切除术及淋巴结清扫术。

结果

中位随访时间为22.4个月[6 - 185个月]。2年和5年的总生存率分别为53%和27%。中位总生存期估计为27个月。“反应者”和“无反应者”患者的2年总生存率分别为67%和26%(P<0.0001)。在组织学反应方面,总生存期(P<0.0001)、局部区域控制(P<0.0036)和无病生存期(P<0.001)均有获益。ypN0组2年总生存率为64%,ypN1组为32%(P<0.0001)。在无淋巴结受累时,中位生存期估计为37个月,而有淋巴结受累时为15个月(P<0.0001)。

结论

我们在生存、耐受性、发病率和死亡率方面的结果与文献中的结果相当。淋巴结的完全组织学反应与局部控制、无病生存期和总生存期改善相关。

相似文献

1
[Long-term outcome of neoadjuvant radiochemotherapy followed by surgery for esophageal cancer: a single institution retrospective study of 102 patients].新辅助放化疗后手术治疗食管癌的长期疗效:一项针对102例患者的单机构回顾性研究
Cancer Radiother. 2015 Aug;19(5):322-30. doi: 10.1016/j.canrad.2015.04.004. Epub 2015 Jul 26.
2
Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.局部晚期食管癌的淋巴结转移:新辅助治疗如何改变其频率和分布。
Ann Surg Oncol. 2011 Dec;18(13):3743-54. doi: 10.1245/s10434-011-1753-9. Epub 2011 May 10.
3
Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.新辅助放化疗后食管癌的淋巴结清扫。
Ann Surg Oncol. 2013 Sep;20(9):3038-43. doi: 10.1245/s10434-013-2988-4. Epub 2013 Apr 28.
4
The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.新辅助放化疗后原发肿瘤完全缓解的食管癌患者残留淋巴结疾病的预后价值。
J Surg Oncol. 2015 Nov;112(6):597-602. doi: 10.1002/jso.24050. Epub 2015 Sep 23.
5
Treatment of clinical T2N0M0 esophageal cancer.临床T2N0M0期食管癌的治疗
Ann Surg Oncol. 2014 Nov;21(12):3739-43. doi: 10.1245/s10434-014-3929-6. Epub 2014 Jul 22.
6
Long-term results of a phase II trial of neoadjuvant chemotherapy followed by esophagectomy for locally advanced esophageal neoplasm.一项针对局部晚期食管肿瘤进行新辅助化疗后行食管切除术的II期试验的长期结果。
Ann Thorac Surg. 2008 Jun;85(6):1930-6; discussion 1936-7. doi: 10.1016/j.athoracsur.2008.01.097.
7
Different recurrence pattern after neoadjuvant chemoradiotherapy compared to surgery alone in esophageal cancer patients.与单纯手术相比,新辅助放化疗后的食管癌患者具有不同的复发模式。
Ann Surg Oncol. 2013 Nov;20(12):4008-15. doi: 10.1245/s10434-013-3102-7. Epub 2013 Jul 10.
8
Predictive Factors of Recurrence in Patients with Pathological Complete Response After Esophagectomy Following Neoadjuvant Chemoradiotherapy for Esophageal Cancer: A Multicenter Study.新辅助放化疗后食管癌食管切除术后病理完全缓解患者复发的预测因素:一项多中心研究
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1357-64. doi: 10.1245/s10434-015-4619-8. Epub 2015 May 27.
9
Refining pathological evaluation of neoadjuvant therapy for adenocarcinoma of the esophagus.优化新辅助治疗食管腺癌的病理评估。
World J Gastroenterol. 2013 Dec 28;19(48):9282-93. doi: 10.3748/wjg.v19.i48.9282.
10
Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.单机构对食管癌腺癌术前与根治性放化疗的回顾性比较
Ann Surg Oncol. 2014 Nov;21(12):3744-50. doi: 10.1245/s10434-014-3795-2. Epub 2014 May 23.